This is the authors' abstract. We don't add key points for this paper.
Funding sources: No external funding. Conflicts of interest: none declared. Dear Editor, Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis (LyP) and borderline cases. LyP is characterized by a chronic course with recurrent papulonodular lesions, which undergo spontaneous regression after weeks or months.1 LyP has an excellent prognosis with a 10‐year disease‐specific survival of almost 100%.2 For patients with limited lesions an expectant policy is a legitimate approach. Treatment can be considered in severe forms of LyP in which the size and number of lesions are extensive or when ulceration, scarring and pruritus are prominent. Previous studies have described that maintenance treatment with low‐dose methotrexate (MTX) can be effective.3 4 5 However, discussions preceding the publication of consensus recommendations revealed controversies regarding the optimal starting dose, maintenance dose, route of administration, duration of MTX treatment and the safety of prolonged MTX treatment.6 These discussions prompted us to evaluate the results of MTX treatment in a Dutch cohort of patients with LyP and to report our current practice guidelines.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bruijn et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: